Previsioni

Acquista	5
Mantieni	0
Vendi	0

Notizie Vai al feed delle notizie

AVITA Medical: study shows 70% cost savings with wound matrix PermeaDerm

A multicenter, randomized study of 40 patients at 11 U.S. burn centers found that the biosynthetic wound matrix PermeaDerm reduced treatment costs by 70% compared with allografts while producing comparable clinical outcomes. Average cost per 1% treated body surface area was $148.70 versus $497.10 for allografts; the primary endpoint was statistically significant (p<0.001). PermeaDerm reduced preparation effort by 95.7%, is ready to use immediately, and showed no product-related adverse events; both groups achieved ≥95% wound healing within eight weeks. » Altro su de.investing.com
Avita Medical expands exclusive distribution for PermeaDerm and adjusts revenue sharing

Avita Medical secured, for a fee of $500,000, a right of first refusal and first negotiation to extend its exclusive distribution territory for PermeaDerm to parts of or the entire EU, the United Kingdom and Australia. The amended agreement with Stedical Scientific raises Avita’s revenue share on sheet products to 67% (with additional increases if gross margins exceed 50%) and on gloves to 80% (with uplifts if gross margins exceed 35%). Avita must achieve at least $1.0 million in revenue shares in 2026 and meet a minimum growth rate of 20% per year through 2030; at the same time Stedical is allowed to serve certain U.S. markets, with Avita applying a 10% markup on manufacturing costs for U.S. sales. Avita also reported Q2 revenue of $21.7 million (+18% y/y) and an adjusted loss of $0.25 per share, after which the stock rose sharply. » Altro su de.investing.com
AVITA Medical receives approval for RECELL GO in Australia and New Zealand

AVITA Medical has received approval for its RECELL GO system from the Australian Therapeutic Goods Administration and has been registered by Medsafe in New Zealand. Exclusive distributor Revolution Surgical plans commercial launch in the coming weeks; the automated system prepares RECELL Spray-On Skin for burn and trauma wounds up to 1,920 cm². AVITA reported revenue of $71.6 million and a gross margin of 82% over the past twelve months but remains unprofitable due to market-building investments; the stock has shown high recent volatility and is rated undervalued by InvestingPro. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Avita Therapeutics ha registrato ricavi pari a 19.02m€ e un utile netto di −6.71m€

(EUR)	giu 2026	YoY
Ricavi	+19.02m	21,69%
Utile lordo	+15.57m	22,74%
Utile netto	−6.71m	20,22%
EBITDA	−4.22m	38,70%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+218.16m€
Numero di azioni	135.22m
Massimo/minimo a 52 settimane	+1,61€ - +0,48€
Dividendi	No
Beta	1,85
Rapporto P/E	−7,08
Rapporto PEG	−0,22
Rapporto P/B	−11,34
Rapporto P/S	+3,37

Profilo aziendale

AVITA Medical Inc. ist ein Unternehmen, das in den Vereinigten Staaten, Australien und dem Vereinigten Königreich regenerative Gewebe herstellt. Das Unternehmen bietet regenerative Produkte für ungedeckte medizinische Bedürfnisse bei Verbrennungen, Traumata, chronischen Wunden sowie dermatologischen und ästhetischen Indikationen, einschließlich Vitiligo. Die patentierte und firmeneigene Plattformtechnologie des Unternehmens bietet Behandlungslösungen, die auf den regenerativen Eigenschaften der eigenen Haut des Patienten basieren. Das Hauptprodukt des Unternehmens ist das RECELL-System, ein Gerät, mit dem medizinisches Fachpersonal eine Suspension von Spray-On-Skin-Zellen aus einer kleinen Probe der eigenen Haut des Patienten herstellen kann, die zur Behandlung von akuten thermischen Verbrennungen bei Patienten ab 18 Jahren eingesetzt wird. Das Unternehmen unterhält eine Forschungskooperation mit der University of Colorado School of Medicine, um den präklinischen Konzeptnachweis für eine Spray-On-Behandlung von genetisch korrigierten Zellen zu erbringen, und eine Forschungskooperation mit dem Houston Methodist Research Institute, um die molekulare Umkehrung der Zellalterung durch ein neuartiges Zellsuspensionsverabreichungssystem zu erforschen. Das Unternehmen war früher unter dem Namen AVITA Therapeutics, Inc. bekannt und änderte im Dezember 2020 seinen Namen in AVITA Medical Inc. AVITA Medical Inc. wurde im Jahr 2000 gegründet und hat seinen Sitz in Valencia, Kalifornien.

Nome	Avita Therapeutics
CEO	Cary G. Vance
Sede centrale	Valencia, ca Stati Uniti
Sito web	avitamedical.com
Settore	Beni voluttuari
Industria	Beni durevoli per la casa
Quotazione in borsa	04/09/2003
Dipendenti	226